Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

There is currently a lack of available treatments that can prevent or modify the progression of neurodegenerative disorders like Alzheimer's disease and Parkinson's disease, which affect millions of people in Europe. Despite robust research efforts to accelerate biomarker discovery, there are few secure, accessible ways for clinical samples and data to be discovered and shared within the research community.

'Alzheimer's and Parkinson's cost millions of lives and will create an estimated economic burden in Europe of €267 billion by 2030,' said project co-Coordinator Pieter Jelle Visser, Associate Professor at the University of Maastricht. 'EPND will answer this massive challenge with a solution on the same scale, bringing together teams, samples and data from across the continent.'

Professor Michele Hu is a Co-Investigator on the project, and UK lead for the Parkinson's disease biomarker collection.

The development of effective treatments requires biomarkers for early detection of disease in individuals, for assessing treatment efficacy, and for patient stratification. Thanks to funding from the Innovative Medicines Initiative (IMI), EPND will begin a five-year effort to establish a self-sustaining network that will support the discovery, harmonization, storage and analysis of high-quality clinical samples and data from neurodegenerative disease research.

Beyond establishing the network, the project aims to create agreed principles to enable access to samples and data, establish fair and transparent governance and processes, and achieve self-sustainability after five years. When complete, it will create a new entity supported by some of the most prestigious medical and research organisations in the EU. This public-private partnership will accelerate and simplify innovation in the areas of R&D, regulatory, clinical and healthcare practices.

Similar stories

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Unique study of vascular disease reaches 20th anniversary

The only project of its kind anywhere that studies patients with all types of acute vascular events - including strokes, heart attacks, aneurysms - in order to develop better diagnostic tests and treatments celebrates its 20th anniversary this month.

DPAG launches “Body, Brain, Behavior: Three Views and a Conversation” in Oxford

The Oxford Book Launch 'Body Brain Behavior - The Need For Conversations' brought together three world leading scientist authors, Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch, with Oxford's neuroscience community on Thursday 7 April 2022.

Little understood brain region linked to how we perceive pain

A new review paper, published in the journal Brain, has shown that a poorly understood region of the brain called the claustrum may play an important role in how we experience pain.